Hyderabad: Amid rising cases of H3N2 Influenza virus in the country and reports of some deaths, Hyderabad-based vaccine manufacturer India BiotechnologyWho developed indigenous Covaxin and intranasal vaccine iNCOVACCNow its founder chairman Dr. Krishna is working on a vaccine for this. Ella Confirmed on Friday.
Speaking to TOI on the sidelines of a one-day CII summit on ‘South [email protected]: Going Beyond Boundaries’, Ella said: “I am a scientist. Of course we are working on this (H3N2 virus vaccine) . We have started. Let’s work and we are expecting that the next pandemic will come in flu. Also I am telling that it is spreading in bird flu, pig and chicken and humans also.” However, he refused to give further details in this regard.
Bharat Biotech had earlier developed a vaccine for H1N1 or swine flu, a subtype of the Influenza A virus that causes respiratory infections, and was working on a more potent H1N1 vaccine around 2015.
H3N2 is also a subtype of Influenza A virus and resulted in the first death in India in early March this year. Stating that she has taken her mind off Covid, Ella said: “I am working on different things now, there is no point in working on what is over.”
Bharat Biotech had earlier said that it will develop an antigen bank of 10 million doses as a stockpile for its nasal COVID-19 vaccine iNCOVACC.
Ella also confirmed that the capacity of iNCOVACC is huge and can be scaled up as needed.
While Bharat Biotech developed iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine, in collaboration with Washington University in St. Louis, the inactivated virus intra-muscular injectable vaccine Covaxin was developed by the company in collaboration with ICMR-NIV.
Speaking to TOI on the sidelines of a one-day CII summit on ‘South [email protected]: Going Beyond Boundaries’, Ella said: “I am a scientist. Of course we are working on this (H3N2 virus vaccine) . We have started. Let’s work and we are expecting that the next pandemic will come in flu. Also I am telling that it is spreading in bird flu, pig and chicken and humans also.” However, he refused to give further details in this regard.
Bharat Biotech had earlier developed a vaccine for H1N1 or swine flu, a subtype of the Influenza A virus that causes respiratory infections, and was working on a more potent H1N1 vaccine around 2015.
H3N2 is also a subtype of Influenza A virus and resulted in the first death in India in early March this year. Stating that she has taken her mind off Covid, Ella said: “I am working on different things now, there is no point in working on what is over.”
Bharat Biotech had earlier said that it will develop an antigen bank of 10 million doses as a stockpile for its nasal COVID-19 vaccine iNCOVACC.
Ella also confirmed that the capacity of iNCOVACC is huge and can be scaled up as needed.
While Bharat Biotech developed iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine, in collaboration with Washington University in St. Louis, the inactivated virus intra-muscular injectable vaccine Covaxin was developed by the company in collaboration with ICMR-NIV.